tbuckley/cabot-search huggingface dataset:
Active Her-2/<b><i>neu</i></b> signal transduction in breast cancer –relevance of a ligand-independent activation mechanism and impact on the efficacy of trastuzumab-based treatment
Authors: G. Hudelist, W. Koestler, J. Attems, K. Czerwenka, R. Mueller, M. Manavi, G. Steger, E. Kubista, C. J. Zielinski, C. F. Singer
Journal: Journal of Clinical Oncology (2004)

649 Background: Proteolytic shedding of the Her-2/neu extracellular domain (ECD) has been demonstrated to initiate receptor phosphorylation and thereby Her-2/neu activation in vitro. The aim of the present work was to investigate the clinical relevance of ECD cleavage for Her-2/neu activation and the clinical relevance of active intracellular Her-2/neu signalling reflected by tyrosine kinase phosphorylation in patients treated with trastuzumab-based therapy. Methods: Sera from 62 patients receiving trastuzumab-based treatment for Her-2/neu over-expressing metastatic breast cancer were analyzed for pre-treatment ECD levels by enzyme-linked immunosorbent assay (ELISA). The degree of Her-2/neu phosphorylation/activation of tumor specimens was assessed by immunohistochemistry using a Her-2/neu phosphorylation state specific antibody (PN2A). The Her-2/neu phosphorylation status was then correlated with the patients' ECD levels and clinical course of disease. Results: Serum ECD levels were significantly higher in 15 (24%) patients with tumours exhibiting activated Her-2/neu as compared to those without detectable Her-2/neu phosphorylation (median 148.2 ng/ml vs. 28.5 ng/ml, p=0.01). Whereas response rate only tended to be higher in patients with Her-2/neu-phosphorylated breast cancer (47% vs. 34%, p=0.197), both uni- an multivariate analyses revealed that the median progression-free survival under trastuzumab-based treatment was significantly longer in patients with Her-2/neu-phosphorylated breast cancer 11.7 (95% CI 5.2 to 18.3) as compared to the progression-free survival of 4.5 (95% CI 3.4 to 5.6, p=0.001) months observed in patients with tumours without phosphorylated Her-2/neu. Conclusions: These data strongly suggest that proteolytic cleavage of the ECD represents a biologically relevant ligand-independent mechanism of Her-2/neu activation in vivo. The influence of Her-2/neu activation status upon the efficacy of trastuzumab merits further investigation in larger prospective trials. No significant financial relationships to disclose.
Abstract 2734: Poly-ligand profiling of plasma samples as a potential predictor of prostate biopsy results
Authors: Xixi Wei, Xiaowei Liu, Radhika Santhanam, Daniel Magee, Anthony Helmstetter, Mark Miglarese, David Spetzler, Xixi Wei
Journal: Cancer Research (2019)

Abstract Prostate cancer is the most common cancer in men, excluding skin cancer, and is also one of the leading causes of cancer death. Currently the prostate-specific antigen (PSA) blood test is employed as an initial screening method in men without symptoms, and patients with blood PSA level higher than 4 ng/mL are commonly recommended for prostate biopsy for definitive diagnosis. However, other non-cancerous conditions may also cause elevation in PSA, such as prostatitis, benign prostatic hyperplasia and prostate intraepithelial neoplasia. Among men with PSA levels of 4-10 ng/mL, only about 1 in 4 will show positive (cancer) biopsy, and for those with PSA levels higher than 10 ng/mL, the chance of having prostate cancer increases to over 50%. Moreover, approximately 15% of men with a PSA levels below 4 ng/mL have a positive prostate biopsy. Because of these scenarios, as well as significant risks associated with prostate biopsies, there is a need for diagnostic adjuncts that provide additional data to inform decisions on whether or not to perform biopsies. Here we describe a method using single stranded oligonucleotide (ssODN) libraries to perform Poly-Ligand Profiling on plasma exosomes from men scheduled for biopsy to classify those with or without a subsequent diagnosis of prostate cancer. Through alternating rounds of positive and negative selection in binding assays, we isolated ssODNs that selectively bound to exosomes from prostate cancer patients (PSA level of at least 4 ng/mL; Gleason Score range 7-8, and at least 3 positive cores from at least 10 biopsy cores) and not to benign cases (all negative cores from at least 10 biopsy cores). An independent test set of 29 prostate cancer cases and 28 benign cases was then evaluated in binding assays. Based on 100 runs of 10-fold cross validation with multiple statistic models, an average successful classification rate of 82% was achieved with an area under the ROC curve of 0.89. While further refinement and testing on larger cohorts are needed, these results suggest that Poly-Ligand Profiling may provide an additional approach to stratify men with suspicious PSA levels for prostate biopsies. Citation Format: Xixi Wei, Xiaowei Liu, Radhika Santhanam, Daniel Magee, Anthony Helmstetter, Mark Miglarese, David Spetzler, Xixi Wei. Poly-ligand profiling of plasma samples as a potential predictor of prostate biopsy results [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2734.
Family History
Authors: Jack Coulehan
Journal: Annals of Internal Medicine (2014)

Ad Libitum17 June 2014Family HistoryJack Coulehan, MD, MPHJack Coulehan, MD, MPHFrom Setauket, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-0088 Audio Reading - “Family History” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Family History," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail a dark ... Author, Article, and Disclosure InformationAffiliations: From Setauket, New York.Current Author Address: Jack Coulehan, MD, MPH; e-mail, John.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Family History” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Family History," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 June 2014Volume 160, Issue 12Page: 863 ePublished: 17 June 2014 Issue Published: 17 June 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Death following self-poisoning with aspirin
Authors: R. K. Ferguson
Journal: JAMA (1970)

Death followed aspirin ingestion in a 23-year-old woman. Since large amounts of aspirin tablets in the gut seem to retard their own absorption, it is essential that serial salicylate determinations be obtained following the ingestion to make certain that continued rise does not occur. Serum salicylate concentration did not correlate with the state of consciousness or magnitude of metabolic disturbance. We question the usefulness of gastric lavage in removing undissolved tablets.
MALPRACTICE SUIT DECIDED.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Books Received
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE AMERICAN BOARD OF INTERNAL MEDICINE
Journal: Annals of Internal Medicine (1937)

Article1 June 1937THE AMERICAN BOARD OF INTERNAL MEDICINEWALTER L. BIERRING, M.D., F.A.C.P.WALTER L. BIERRING, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-12-1746 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe growth of specialism in America is in line with progress, and significant of the remarkable advancement of knowledge in every field of medicine since the opening of the century.That modern diagnostic technic is based on special training is obvious, and its influence towards specialized medical and surgical practice is likewise apparent.In the evolution of American medical schools during the past three decades, uniformity of curriculum and hours of study constituted all too frequently the principal standard of measurement, and in consequence, courses in certain specialties occupied a large part of the undergraduate curriculum.This was reflected in... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Des Moines, Iowa*Presented at the St. Louis meeting of the American College of Physicians, April 22, 1937. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1937Volume 10, Issue 12Page: 1746-1751KeywordsUndergraduates ePublished: 1 December 2008 Issue Published: 1 June 1937 PDF downloadLoading ...
Abstract 14664: Reduced Activin Like Kinase 1 Activity Promotes Cardiac Fibrosis in Heart Failure
Authors: Kevin Morine, Vikram Paruchuri, Xiaoying Qiao, Emily Mackey, Mark Aronovitz, Pilar Alcaide, Robert Blanton, Richard Karas, Navin K Kapur
Journal: Circulation (2015)

Introduction: Activin receptor like kinase 1 (ALK1) mediates signaling via transforming growth factor beta-1 (TGFb1), a pro-fibrogenic cytokine. No studies have defined a role for ALK1 in heart failure. We tested the hypothesis that reduced ALK1 expression promotes maladaptive cardiac remodeling in heart failure. Methods and Results: ALK1 mRNA expression was quantified by RT-PCR in left ventricular (LV) tissue from patients with end-stage heart failure and compared to control LV tissue obtained from the National Disease Research Interchange (n=8/group). Compared to controls, LV ALK1 mRNA levels were reduced by 85% in patients with heart failure. Next, using an siRNA approach, we tested whether reduced ALK1 levels promote TGFb1-mediated collagen production in human cardiac fibroblasts. Treatment with an ALK1 siRNA reduced ALK1 mRNA levels by 75%. Compared to control, TGFb1-mediated Type I collagen and pSmad-3 protein levels were 2.5-fold and 1.7-fold higher, respectively, after ALK1 depletion. To explore a role for ALK1 in heart failure, ALK1 haploinsufficient (ALK1) and wild-type mice (WT; n=8/group) were studied 2 weeks after thoracic aortic constriction (TAC). Compared to WT, baseline LV ALK1 mRNA levels were 50% lower in ALK1 mice. Both LV and lung weights were higher in ALK1 mice after TAC. Cardiomyocyte area and LV mRNA levels of BNP, RCAN, and b-MHC were increased similarly, while SERCa levels were reduced in both ALK1 and WT mice after TAC. Compared to WT, LV fibrosis (Figure) and Type 1 Collagen mRNA and protein levels were higher among ALK1 mice. Compared to WT, LV fractional shortening (48±12 vs 26±10%, p=0.01) and survival (Figure) were lower in ALK1 mice after TAC. Conclusions: Reduced LV expression of ALK1 is associated with advanced heart failure in humans and promotes early mortality, impaired LV function, and cardiac fibrosis in a murine model of heart failure. Further studies examining the role of ALK1 and ALK1 inhibitors on cardiac remodeling are required.
A representative value for whole-day BP monitoring
Authors: M. A. Weber
Journal: JAMA (1982)

Shorter-term alternatives to 24-hour monitoring of BP were analyzed in six hypertensive patients. Average BPs during the 24-hour period were lower than averages during a two-hour morning period or those based on either three readings or a single reading taken at 8 AM. The systolic and diastolic BP two-hour averages correlated more strongly with the 24-hour averages than did the three-reading or single-reading alternatives. Thus, the average of serial BP readings obtained during a two-hour morning period is a consistent predictor of the whole-day BP and represents it more closely than the conventionally used single reading. (<i>JAMA</i>1982;248:1626-1628)
Ugeskrift for Laeger, Copenhagen
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Provincial Medical Journal
Journal: BMJ (1843)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Provincial Medical Journal Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Postoperative Nomogram for 12-Year Sarcoma-Specific Death
Authors: M. W. Kattan
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Few published studies have analyzed risk factors for sarcoma-specific death. We developed and internally validated a nomogram that combines the factors to predict the probability of 12-year sarcoma-specific death using a database of 2,136 prospectively followed adult patients treated at a single institution. PATIENTS AND METHODS: Nomogram predictor variables included age at diagnosis, tumor size (≤ 5, 5 to 10, or > 10 cm), histologic grade (high or low), histologic subtype (fibrosarcoma, leiomyosarcoma, liposarcoma, malignant fibrous histiocytoma, malignant peripheral nerve tumor, synovial, or other), depth (superficial or deep), and site (upper extremity, lower extremity, visceral, thoracic or trunk, retrointraabdominal, or head or neck). Death from sarcoma or treatment complication was the predicted end point. Three prediction methods were compared, Kaplan-Meier analysis of all possible subsets, recursive partitioning, and Cox proportional hazards regression analysis. The concordance index was used as an accuracy measure with bootstrapping to correct for optimistic bias. RESULTS: Sarcoma-specific death at 12 years was 36% (95% confidence interval, 33% to 39%). The bootstrap-corrected concordance indices were as follows: Kaplan-Meier, 0.69; recursive partitioning, 0.74; and Cox regression, 0.77. A nomogram was drawn on the basis of the Cox regression model. This nomogram was internally validated using bootstrapping and shown to have excellent calibration. CONCLUSION: A nomogram has been developed to predict 12-year sarcoma-specific death. This tool may be useful for patient counseling, follow-up scheduling, and clinical trial eligibility determination.
Alterations in Estrogen Levels during Development Affects the Skeleton: Use of an Animal Model
Authors: Silvia Migliaccio, Retha R. Newbold, John A. McLachlan, Kenneth S. Korach
Journal: Environmental Health Perspectives (1995)

Exposure to estrogens during various stages of development has been shown to irreversibly influence responsive target organs.The recent finding of the presence of estrogen receptor in both osteoblasts and osteoclasts has suggested a direct role of steroid hormones on bone tissue.Furthermore, estrogens have important effects on bone turnover in both humans and experimental animal models.Thus, this tissue is now regarded as a specific estrogen target tissue.To investigate whether a short-term developmental exposure to estrogens can influence bone tissue, we have injected female mice with diethylstilbestrol (DES) from day 1 through day 5 of life.Additionally, a group of pregnant female mice were injected with different doses of DES from day 9 through 16 of pregnancy.Mice were then weaned at 21 days of age, and effects on bone tissue of the female mice were evaluated in adulthood (7-12 months of age).These short-term treatments did not affect body weight of exposed mice.However, a dose-dependent increase in bone mass, both in the trabecular and compact compartments, was observed in the DES-exposed female offspring.Furthermore, femurs from DES- exposed females were shorter than femurs from controls.A normal skeletal mineralization accompanied these changes in the bone tissue.In fact, a parallel increase in total calcium content of the skeleton was found in concomitance with the increase in bone mass.Estrogen treatment induced an increase in the amount of mineralized skeleton when compared to untreated controls.In summary, this report shows that alterations of estrogen lev- els during development can influence the early phases of bone tissue development inducing permanent changes in the skeleton.These changes appear to be related to bone cell programming in early phases of life.
VISIONS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epicardial fat sign in the diagnosis of pericardial effusion
Authors: E. W. Carsky
Journal: JAMA (1980)

PERICARDIAL effusion is most often present in patients with uremia, viral pericarditis, and malignant neoplasms. It is also observed in many other conditions, including Dressler's syndrome, myxedema, collagen vascular diseases, congestive heart failure, lymphoma, sarcoidosis, and bacterial and tuberculous pericarditis. Echocardiography is the method of choice for the diagnosis of pericardial effusion. This technique is highly accurate and reliable, but it is not used in all patients because frequently pericardial effusion is not clinically suspected. However, most patients with pericardial disease have plain chest roentgenograms, and in some of these the "water bottle" configuration of the heart leads to the proper diagnosis. The authors have found the epicardial fat sign to be useful in the diagnosis of pericardial effusion in patients in whom this condition is clinically not suspected and in whom the chest films show a normal heart configuration (Fig 1). The epicardial fat sign as an aid in
Correction
Journal: BMJ (1962)

ANY QUESTIONS? MEDIBRALrBy an elaborate series of absorptions and elutions he has shown that the rheumatoid factor is most probably an antibody against denatured human gamma globulin.As with most antibodies, its ability to cross-react with similar proteins of other species is a function of the avidity of the antibody for its antigen.Consequently, absorption of rheumatoid sera by appropriately treated human gamma globulin removes all the rheumatoid factor activity, as detected by any test, whereas absorption by appropriately denatured rabbit gamma globulin only removes the cross- reacting antibodies-i.e., those of high avidity-and leaves behind the more specifically anti-human antibodies, so that they are still detectable by human gamma-globulin reactants such as participate in the latex or streptococcal tests.